ES2155093T3 - Nuevos inhibidores de la uridina fosforilasa (urdpasa) y de la dihidrouracil deshidrogenasa (dhudasa). - Google Patents

Nuevos inhibidores de la uridina fosforilasa (urdpasa) y de la dihidrouracil deshidrogenasa (dhudasa).

Info

Publication number
ES2155093T3
ES2155093T3 ES94929398T ES94929398T ES2155093T3 ES 2155093 T3 ES2155093 T3 ES 2155093T3 ES 94929398 T ES94929398 T ES 94929398T ES 94929398 T ES94929398 T ES 94929398T ES 2155093 T3 ES2155093 T3 ES 2155093T3
Authority
ES
Spain
Prior art keywords
sub
compounds
urdpasa
dhudasa
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94929398T
Other languages
English (en)
Inventor
Kouni Mahmoud H El
Fardos N M Naguib
Raymond F Schinazi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2155093T3 publication Critical patent/ES2155093T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PRESENTAN NUEVOS COMPUESTOS QUE SON EFECTIVOS PARA INHIBIR LA ACTIVIDAD DE LA DHUDASA O DE URDPASA. LOS COMPUESTOS TIENEN LA FORMULA GENERAL (I) O (II), EN DONDE X ES S O SE; Y ES 1, F, CL, BR, METOXIDO, BENZILO, SELENILFENILO O TIOFENILO, Y R1 ES UNA COLA DE ACICLO QUE TIENE LA FORMULA GENERAL (III) EN DONDE R2 ES H, CH{SUB,2}OH, O CH{SUB,2}NH{SUB,2}; R3 ES OH, NH{SUB,2}, O OCOCH{SUB,2}CH{SUB,2}CO{SUB,2}H; Y R4 ES O, S, O CH{SUB,2}. LOS COMPUESTOS PUEDEN UTILIZARSE EN COMPOSICIONES FARMACEUTICAS, JUNTO CON DIFERENTES AGENTES QUIMIOTERAPEUTICOS PARA INCREMENTAR LA EFICACIA DEL TRATAMIENTO. LOS COMPUESTOS TAMBIEN PUEDEN USARSE EN METODOS PARA EL TRATAMIENTO DE PACIENTES MEDIANTE COADMINISTRACION O ADMINISTRACION SECUENCIAL DE LOS COMPUESTOS INHIBIDORES DE ENZIMAS CON UN AGENTE QUIMIOTERAPEUTICO EFECTIVO PARA EL TRATAMIENTO DE CANCERES O INFECCIONES VIRALES, FUNGALES, BACTERIANAS O PARASITICAS. LOS COMPUESTOS TIENEN UTILIDAD ADICIONAL EN LA MEJORA DE PROCEDIMIENTOS PARA LA FORMACION DE IMAGENES. ADEMAS, PUEDEN ADMINISTRASE SOLOS PARA EVITAR Y/O TRATAR ENFERMEDADES DEL CATABOLISMO DE LA PIRIMIDINA Y OTROS DESORDENES FISIOLOGICOS.
ES94929398T 1993-11-02 1994-09-30 Nuevos inhibidores de la uridina fosforilasa (urdpasa) y de la dihidrouracil deshidrogenasa (dhudasa). Expired - Lifetime ES2155093T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/146,838 US5476855A (en) 1993-11-02 1993-11-02 Enzyme inhibitors, their synthesis and methods for use

Publications (1)

Publication Number Publication Date
ES2155093T3 true ES2155093T3 (es) 2001-05-01

Family

ID=22519188

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94929398T Expired - Lifetime ES2155093T3 (es) 1993-11-02 1994-09-30 Nuevos inhibidores de la uridina fosforilasa (urdpasa) y de la dihidrouracil deshidrogenasa (dhudasa).

Country Status (9)

Country Link
US (3) US5476855A (es)
EP (1) EP0725641B1 (es)
JP (1) JP3621102B2 (es)
AT (1) ATE198046T1 (es)
AU (1) AU699914B2 (es)
DE (1) DE69426423T2 (es)
ES (1) ES2155093T3 (es)
PT (1) PT725641E (es)
WO (1) WO1995012400A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476855A (en) * 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
EP0748316B1 (en) * 1994-02-28 2002-05-08 Sunkyong Industries Co., Ltd. Pyrimidine acyclonucleoside derivatives
US5811073A (en) * 1995-06-19 1998-09-22 President And Fellows Of Harvard College Method for radioisotopic detection and localization of inflammation in a host
US5719132A (en) * 1996-06-27 1998-02-17 Bristol-Myers Squibb Company Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
US6306909B1 (en) 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
US6177437B1 (en) * 1998-09-04 2001-01-23 University Of Massachusetts Medical Center Inhibitors of Herpes Simplex virus uracil-DNA glycosylase
PT1255738E (pt) * 2000-01-25 2012-06-19 Neurocrine Biosciences Inc Antagonistas do receptor da hormona de libertação da gonadotrofina e métodos relacionados com os mesmos
US7501429B2 (en) * 2001-04-11 2009-03-10 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
CA2448160A1 (en) * 2001-05-25 2002-12-05 Queen's University At Kingston Heterocyclic beta-amino acids and their use as anti-epileptogenic agents
WO2005012309A1 (fr) * 2003-08-04 2005-02-10 Valery Khazhmuratovich Zhilov Bioisosteres cycliques issus d'un systeme purine et composition pharmaceutique a base desdits bioisosteres
NZ555176A (en) * 2004-12-03 2010-03-26 Adherex Technologies Inc Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs
US20100158966A1 (en) * 2005-05-24 2010-06-24 Ted Reid Selenium-based biocidal formulations and methods of use thereof
EP1898706B1 (en) * 2005-05-24 2018-04-04 Selenium, Ltd. Selenium-based biocidal formulations and methods of use thereof
US9370187B2 (en) 2005-05-24 2016-06-21 Selenium, Ltd. Selenium-based biocidal formulations and methods of use thereof
US20100158967A1 (en) * 2005-05-24 2010-06-24 Ted Reid Selenium-based biocidal formulations and methods of use thereof
US8236337B2 (en) * 2005-05-24 2012-08-07 Selenium, Ltd. Anti-microbial orthodontic compositions and appliances and methods of production and use thereof
JP5113752B2 (ja) 2005-08-22 2013-01-09 メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド Ｌｙｎキナーゼの活性を調節し、関連する疾患を治療するための方法および製剤
CA2678813A1 (en) * 2007-02-20 2008-08-28 Melior Pharmaceuticals I, Inc. Methods of identifying activators of lyn kinase
CA2693809A1 (en) * 2007-07-23 2009-01-29 Melior Discovery, Inc. Methods of activating irs-1 and akt
US7998967B2 (en) 2008-03-03 2011-08-16 Tosk, Incorporated Methotrexate adjuvants to reduce toxicity and methods for using the same
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
CA2777546C (en) * 2009-10-14 2019-11-05 Elion Oncology Llc Treating neurotoxicity associated with combinations of 5-fu or its prodrugs and dpd inhibitors
US20130158055A1 (en) 2010-05-28 2013-06-20 Andrew G. Reaume Prevention Of Pancreatic Beta Cell Degeneration
SG11201909406VA (en) 2017-04-10 2019-11-28 Melior Pharmaceuticals I Inc Treatment of adipocytes
US11446303B2 (en) 2019-06-21 2022-09-20 Tosk, Inc. Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
WO2025260023A1 (en) * 2024-06-14 2025-12-18 Spiral Therapeutics, Inc. Methods of treating otic disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755295A (en) * 1969-10-24 1973-08-28 Syntex Corp 1-(2-amino-2-deoxy-{62 -d-ribofuranosyl) pyrimidines and derivatives thereof
US3687931A (en) * 1970-03-19 1972-08-29 Syntex Corp Halogenated purine and pyrimidine nucleosides and process therefor
JPS5738774A (en) * 1980-08-19 1982-03-03 Chugai Pharmaceut Co Ltd Uracil derivative and its preparation
US4868187A (en) * 1980-09-16 1989-09-19 Syntex (U.S.A.) Inc. Anti-viral N-substituted pyrimidines
US4613604A (en) * 1985-07-31 1986-09-23 Brown University Research Foundation Hydroxymethyl derivatives of 5-benzylacyclouridine and 5-benzoyloxybenzylacyclouridine and their use as potentiators for 5-fluoro-2'-deoxyuridine
ES2013664A6 (es) * 1988-03-31 1990-05-16 Mitsubishi Chem Ind Un procedimiento para preparar derivados de nucleosidos de aciclopiramidina sustituidos en la posicion 6.
US5077280A (en) * 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections
CA2039039C (en) * 1990-03-29 2001-05-15 Tadashi Miyasaka Pyrimidine nucleoside derivative and antiviral agent containing the derivative as active ingredient
US5141943A (en) * 1990-04-12 1992-08-25 Brown University Research Foundation 5-benzyl barbiturate derivatives
US5476855A (en) * 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
KR0151811B1 (ko) * 1993-12-21 1998-10-15 강박광 신규한 항바이러스성 2,4-피리미딘디온 유도체 및 그의 제조방법

Also Published As

Publication number Publication date
JPH09507054A (ja) 1997-07-15
DE69426423T2 (de) 2001-07-12
EP0725641A4 (es) 1996-09-04
US5721241A (en) 1998-02-24
USRE37623E1 (en) 2002-04-02
DE69426423D1 (de) 2001-01-18
AU7847694A (en) 1995-05-23
JP3621102B2 (ja) 2005-02-16
WO1995012400A1 (en) 1995-05-11
EP0725641B1 (en) 2000-12-13
EP0725641A1 (en) 1996-08-14
AU699914B2 (en) 1998-12-17
ATE198046T1 (de) 2000-12-15
PT725641E (pt) 2001-05-31
US5476855A (en) 1995-12-19

Similar Documents

Publication Publication Date Title
ES2155093T3 (es) Nuevos inhibidores de la uridina fosforilasa (urdpasa) y de la dihidrouracil deshidrogenasa (dhudasa).
AR018732A1 (es) Iminoazucares alquilados para prevenir, reducir o revertir la resistencia a la multidroga en el tratamiento quimioterapeutico y composicionfarmaceutica que los contiene.
EA200300036A1 (ru) Комбинации ингибиторов дипептидилпептидазы iv и других антидиабетических агентов для лечения сахарного диабета
KR880012218A (ko) 캘폰 유도체를 사용한 다발성 경화증의 치료방법
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
EA200000718A1 (ru) Композиции целекоксиба
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
BR9913319A (pt) Composições e métodos para tratamento de doenças mitocondriais
PE30891A1 (es) Composiciones y metodos terapeuticos sinergicos
RU94041223A (ru) Средство для лечения мотонейроновых заболеваний
RU92016534A (ru) Синергетические терапевтические композиции и способы достижения синергетического терапевтического эффекта
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
CO5200778A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis
EA200001010A1 (ru) Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии
EA199900542A1 (ru) Соединения сульфоновой кислоты или сульфониламино-n-(гетероаралкил)-азагетероциклиламида
RU94044356A (ru) Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
KR950703527A (ko) 프로스타글란딘 유도체
CO5160295A1 (es) Nuevas combinaciones farmaceuticas para inhibidores de la nos cionalmente un ssri
ES2092646T3 (es) Metanoantracenos como antagonistas de dopamina.
RU94037233A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения лекарственноустойчивых новообразований
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
CO4960654A1 (es) Metodo para el tratamiento de enfermedades fisiologicas relacionadas con el uso o con las secuelas provocadas por el uso de la cocaina u otros estimulantes psicomotores
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
AR041069A1 (es) Composicion de tolterodina liquida oral

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 725641

Country of ref document: ES